Key Facts

Invested since 2021
Based in International

About the company

team cutanos

Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible drug delivery system called the Langerhans Cell Targeted Delivery System (LC-TDS). With this technology, the company aims to realize innovative immunotherapies in conjunction with minimally invasive administration. As a spin-off of the Max Planck Institute of Colloids and Interfaces, Cutanos will demonstrate the full range of its platform technology from their headquarter in Austrian capital of Vienna, financed by an equally motivated investment consortium (including KHAN-I, HTGF and IST cube).

Do you want to

know more about this company?

Zum Artikel

Dr. Katharina Severin Investment Manager

Dr. Katharina SeverinInvestment Manager

cutanos in the news

Cutanos Gründerteam Zum Artikel

News

5. July 2021

Cutanos closes first financing round with investor consortium from Austria and Germany

More startups from Life Sciences